Suppr超能文献

评估利伐沙班与维生素K拮抗剂在心房颤动中的肾脏获益:基于真实世界证据的系统评价和荟萃分析

Evaluating Renal Benefits of Rivaroxaban Versus Vitamin K Antagonists in Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-world Evidence.

作者信息

Dinh Phong Phan, Quang Ho Tri Huynh, Pham Hung Manh, Nguyen Hai Hoang, Ton Minh That, Tran Giang Song, Vu Nga Quynh, Pham Hung Nhu, Cao Son Luong, Hoang Sy Van

机构信息

Vietnam National Heart Institute, Bach Mai Hospital Hanoi, Vietnam.

Hanoi Medical University Hanoi, Vietnam.

出版信息

Eur Cardiol. 2024 Jun 13;19:e05. doi: 10.15420/ecr.2024.07. eCollection 2024.

Abstract

BACKGROUND

AF is a global health concern, with systemic complications including renal dysfunction. This systematic review and meta-analysis compares the effects of rivaroxaban, a Factor Xa inhibitor, and vitamin K antagonists (VKAs) on renal outcomes in AF patients.

METHODS

The study protocol is registered in PROSPERO (ID: CRD42023462756). We systematically searched the PubMed, Embase and Cochrane Library databases from 1 January 2017 to 30 June 2023 for real-world studies comparing the effects of rivaroxaban and VKAs on renal outcomes in AF patients, including acute kidney injury, a .30% decrease in estimated glomerular filtration rate, doubling of serum creatinine and worsening renal function. Subgroup analyses targeted diabetes, pre-existing kidney disease, the elderly (age .65 years) and Asian populations. The risk of bias was assessed used the Robins-I tool. HRs and 95% CIs were synthesised through a random-effects model. Two sensitivity analyses were performed, using a fixed-effects model and excluding conference abstracts.

RESULTS

We identified 1,666 records. After screening, 14 studies comparing rivaroxaban and VKAs were included. Rivaroxaban exhibited superiority over VKAs in preventing: acute kidney injury (HR 0.68; 95% CI [0.61.0.77]; p<0.00001); a .30% decrease in estimated glomerular filtration rate (HR 0.71; 95% CI [0.60.0.84]; p<0.0001); doubling of serum creatinine (HR 0.50; 95% CI [0.36.0.70]; p<0.0001); and worsening renal function (HR 0.56; 95% CI [0.45.0.69]; p<0.00001). Subgroup and sensitivity analyses consistently confirmed rivaroxaban's favourable effects on renal outcomes in diabetes, pre-existing kidney disease, the elderly and Asian populations.

CONCLUSION

Our findings support the preference of rivaroxaban over VKAs for renal outcomes in AF. The findings endorse rivaroxaban as the preferred anticoagulant to mitigate renal complications, offering clinicians valuable insights for tailored strategies.

摘要

背景

房颤是一个全球性的健康问题,会引发包括肾功能障碍在内的全身并发症。本系统评价和荟萃分析比较了Xa因子抑制剂利伐沙班和维生素K拮抗剂(VKA)对房颤患者肾脏结局的影响。

方法

该研究方案已在国际前瞻性系统评价注册库(PROSPERO)注册(注册号:CRD42023462756)。我们系统检索了PubMed、Embase和Cochrane图书馆数据库,检索时间为2017年1月1日至2023年6月30日,以查找比较利伐沙班和VKA对房颤患者肾脏结局影响的真实世界研究,包括急性肾损伤、估计肾小球滤过率下降≥30%、血清肌酐翻倍和肾功能恶化。亚组分析针对糖尿病、既往有肾脏疾病、老年人(年龄>65岁)和亚洲人群。使用Robins-I工具评估偏倚风险。通过随机效应模型综合分析风险比(HR)和95%置信区间(CI)。进行了两项敏感性分析,分别采用固定效应模型并排除会议摘要。

结果

我们共识别出1666条记录。经过筛选,纳入了14项比较利伐沙班和VKA的研究。在预防以下情况方面,利伐沙班优于VKA:急性肾损伤(HR 0.68;95%CI[0.61,0.77];p<0.00001);估计肾小球滤过率下降≥30%(HR 0.71;95%CI[0.60,0.84];p<0.0001);血清肌酐翻倍(HR 0.50;95%CI[0.36,0.70];p<0.0001);以及肾功能恶化(HR 0.56;95%CI[0.45,0.69];p<0.00001)。亚组分析和敏感性分析一致证实了利伐沙班对糖尿病、既往有肾脏疾病、老年人和亚洲人群肾脏结局的有利影响。

结论

我们的研究结果支持在房颤患者的肾脏结局方面,优先选择利伐沙班而非VKA。这些结果认可利伐沙班作为减轻肾脏并发症的首选抗凝药物,为临床医生制定个性化策略提供了有价值的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17d2/11231818/2fdf0594f293/ecr-19-e05-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验